A Phase 1 interventional study of Comparator: amlodipine besylate and Comparator: Placebo in Hypertension, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-11.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 155th largest by enrollment of the 186 interventional ones that give a count, is one of 14 that started in 2008, is one of 17 in phase 1, and was the 68th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
33 studies in Hypertension by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 33 finished, 27 (82%) have results posted.
Among the 33 studies in Hypertension by Merck & Co., Inc, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2008, is one of 17 in phase 1, and was the 6th registered.
Merck & Co., Inc’s Hypertension studies by the year they started, since 1990.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Merck & Co., Inc’s 33 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate methodologies for measuring pedal edema associated with calcium channel blockers in middle-aged and elderly subjects and patients with hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
amlodipine
Drug: Comparator: amlodipine besylate
Placebo to amlodipine
Drug: Comparator: Placebo
Two 5 mg tablets amlodipine daily for 6 weeks.
Two 5 mg tablets placebo to amlodipine daily for 6 weeks
Change From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2
Segmental biomimpedance was measured using a multifrequency analyzer (ImpediMed SFB7). The device was used to measure impedance (measured in Ohms) of a small current traveling between leads placed at the ankle and knee. Least Squares Mean Difference from Baseline in impedance is the primary endpoint.
Time frame: Baseline and 2 weeks
Change From Baseline in Foot Volume by Water Displacement (Weight of Water Displaced) at Week 2
Least Squares Mean Difference from Baseline
Time frame: Baseline and 2 weeks
Participants were recruited across 3 Phase I clinical research units in the US. Participants participated from July 2008 to March 2009.
| Milestone | Amlodipine 10 Milligrams | Placebo |
|---|---|---|
| Started | 24 | 23 |
| Completed | 24 | 22 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
Segmental biomimpedance was measured using a multifrequency analyzer (ImpediMed SFB7). The device was used to measure impedance (measured in Ohms) of a small current traveling between leads placed at the ankle and knee. Least Squares Mean Difference from Baseline in impedance is the primary endpoint.
| Ohms | Amlodipine 10 Milligrams | Placebo |
|---|---|---|
| Change From Baseline in Segmental Bioimpedance Measurements at 10 Kilohertz (KHz) at Week 2 | -7.9 ± 20.7 | 3.8 ± 17.0 |
Least Squares Mean Difference from Baseline
| Grams | Amlodipine 10 Milligrams | Placebo |
|---|---|---|
| Change From Baseline in Foot Volume by Water Displacement (Weight of Water Displaced) at Week 2 | 44.8 ± 64.8 | 5.8 ± 53.2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amlodipine 10 Milligrams | — | 0/24 (0%) | 17/24 (70.8%) |
| Placebo | — | 0/23 (0%) | 16/23 (69.6%) |
| Event | Amlodipine 10 Milligrams | Placebo |
|---|---|---|
| Oedema PeripheralGeneral disorders | 12/24 | 9/23 |
| Accidental OverdoseInjury, poisoning and procedural complications | 3/24 | 2/23 |
| Tension HeadacheNervous system disorders | 1/24 | 2/23 |
| NauseaGastrointestinal disorders | 1/24 | 1/23 |
| VomitingGastrointestinal disorders | 0/24 | 1/23 |
| InflammationGeneral disorders | 0/24 | 1/23 |
| Viral InfectionInfections and infestations | 0/24 | 1/23 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 1/24 | 1/23 |
| HeadacheNervous system disorders | 0/24 | 1/23 |
| PalpitationsCardiac disorders | 1/24 | 0/23 |
| Age, Continuous(years) | Amlodipine 10 Milligrams | Placebo | Total |
|---|---|---|---|
| Mean | 58.4 ± 5.6 | 59.6 ± 6.2 | 59.0 ± 5.9 |
| Sex: Female, Male(Participants) | Amlodipine 10 Milligrams | Placebo | Total |
|---|---|---|---|
| Female | 13 | 11 | 24 |
| Male | 11 | 12 | 23 |
| Body Mass Index(kg/m^2) | Amlodipine 10 Milligrams | Placebo | Total |
|---|---|---|---|
| Mean | 28.2 ± 2.9 | 29.0 ± 2.7 | 28.6 ± 2.8 |
No study locations are listed for this record.
The record gives a start of Jul 2008, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine